Type 2 Diabetes in US 2026 | Symptoms & Treatment

Type 2 Diabetes in America 2026

Type 2 diabetes has become one of the most pervasive and costly chronic diseases in the United States, and the numbers heading into 2026 make for sobering reading. The Centers for Disease Control and Prevention (CDC) updated its National Diabetes Statistics Report on January 21, 2026 — the most current federal data available as of today — confirming that over 40.1 million Americans, or 12% of the entire US population, are living with diabetes. Of those, an estimated 36 to 38 million have type 2 diabetes, which accounts for 90 to 95% of all diagnosed diabetes cases in the country. Another 115.2 million American adults — more than 2 in 5 — have prediabetes, the clinical precursor to type 2 diabetes, and a staggering 8 in 10 of them don’t know it. Stacked together, these two conditions affect well over 150 million Americans, making type 2 diabetes and its pipeline one of the defining public health challenges of our time.

What sets the 2026 picture apart from previous years is the collision of two powerful and competing forces. On one hand, GLP-1 receptor agonist medications — including Ozempic, Wegovy, and Mounjaro — have emerged as the most transformative pharmacological tools the diabetes and obesity field has seen in decades, with more than 1 in 4 adults with diagnosed diabetes now using these drugs and US adult obesity rates falling for the first time in years according to a March 2026 Gallup survey. On the other hand, the percentage of Americans diagnosed with diabetes has hit 13.8% — the highest level ever recorded in Gallup’s ongoing surveys — confirming that reductions in obesity have not yet translated into fewer diabetes diagnoses. The disease pipeline remains full, the economic burden is measured in hundreds of billions of dollars annually, and racial, geographic, and socioeconomic disparities in type 2 diabetes prevalence and outcomes remain wide and stubborn. This article compiles every verified, government-sourced type 2 diabetes statistic available in the United States as of March 2026.

Interesting Type 2 Diabetes Facts in the US 2026

The facts below are drawn from the CDC National Diabetes Statistics Report (updated January 21, 2026), the CDC NCHS Data Brief No. 516 (November 2024), the CDC NHIS 2024 Data Brief No. 537 (August 2025), the American Diabetes Association Economic Report (2022), and the Gallup National Health and Well-Being Index (2025, published early 2026). These represent the most current, government-verified data points on type 2 diabetes in the United States available today.

Source: CDC National Diabetes Statistics Report, updated January 21, 2026; CDC NCHS Data Brief No. 516, November 2024; CDC NHIS Data Brief No. 537, August 2025; ADA Economic Costs of Diabetes in the U.S. 2022, published Diabetes Care December 2023; Gallup National Health and Well-Being Index, March 2026

These facts capture a country in the grip of a type 2 diabetes epidemic that shows no signs of reversing, even as treatment advances offer genuine hope for individuals who can access them. The headline figure — 40.1 million Americans with diabetes, updated directly by the CDC on January 21, 2026 — represents the most current and authoritative national estimate available. But the prediabetes figure may be more alarming: 115.2 million adults with prediabetes, the vast majority of whom are unaware of their condition, represent an enormous incoming wave of potential type 2 diagnoses unless aggressive prevention efforts are scaled. The Gallup 2025 survey finding — that Americans diagnosed with diabetes now stand at 13.8%, the highest ever in their series — confirms that even as GLP-1 medications are reducing obesity rates, the diabetes population continues to grow because once someone is diagnosed, they remain diagnosed regardless of subsequent weight changes.

Type 2 Diabetes Prevalence Trends in the US 2026 — Historical Statistics

Understanding where type 2 diabetes stands in 2026 requires understanding how dramatically its prevalence has grown over the past two decades. The CDC’s National Health and Nutrition Examination Survey (NHANES) and National Health Interview Survey (NHIS) have tracked this rise across multiple cycles, providing one of the most comprehensive longitudinal records of any chronic disease in American public health history.

Source: CDC NCHS Data Brief No. 516, November 2024 (NHANES August 2021–August 2023); CDC National Diabetes Statistics Report, January 21, 2026; Gallup National Health and Well-Being Index, 2025 / Patient Care Online, March 2026

The historical trend in type 2 diabetes prevalence in the US tells a story of unrelenting escalation over more than two decades of federal surveillance. From a total adult diabetes prevalence of under 9% in 1999–2000 — when NHANES first began providing systematic national estimates — to 15.8% in the most recent 2021–2023 NHANES cycle, the overall growth represents a 77% increase in adult diabetes prevalence across the span covered by this data. The CDC’s January 2026 National Diabetes Statistics Report, using the most current available national data, places total diabetes at 12% of the full US population — a figure that, when translated to raw numbers, comes to 40.1 million people. And the Gallup 2025 National Health and Well-Being Index — released in early 2026 and based on surveys of more than 16,900 US adults across the first three quarters of 2025 — found 13.8% of respondents reporting a diabetes diagnosis, the highest figure that survey series has ever recorded.

Perhaps most important to grasp about this long-term trend is what it reveals about the effectiveness of prevention efforts to date. Despite the launch of the National Diabetes Prevention Program (DPP) in 2010, significant investments in public health messaging, and — most recently — the rapid spread of GLP-1 medications that demonstrably reduce obesity, every single surveillance cycle has shown higher diabetes prevalence than the last. Gallup’s researchers made the observation directly in their 2025 findings: obesity reductions driven by GLP-1 adoption have not yet translated into measurable declines in diabetes diagnoses, because diabetes is a lifetime diagnosis — once it is recorded, the person remains in the diagnosed population regardless of any subsequent improvement in metabolic health. The type 2 diabetes prevalence trend in 2026 is not reversing. It is still rising.

Type 2 Diabetes by Gender in the US 2026

Men and women are not equally affected by type 2 diabetes in the United States, and the latest federal surveillance data — from the CDC NHANES August 2021–August 2023 cycle, published in NCHS Data Brief No. 516 (November 2024) — provides the clearest and most current picture of these sex-based disparities in diabetes prevalence available as of March 2026.

Source: CDC NCHS Data Brief No. 516, November 2024 (NHANES August 2021–August 2023); CDC NHIS Data Brief No. 537, August 2025; NIDDK Diabetes Statistics, updated October 2025

The gender gap in type 2 diabetes prevalence is consistent and statistically significant across every data source reviewed. Men carry a meaningfully higher burden of total diabetes — at 16.6% age-adjusted versus 12.2% for women — a difference of more than 4 percentage points that has been persistent across multiple NHANES cycles. The undiagnosed diabetes gap is also wider for men: 4.9% of men have diabetes they don’t know about, compared to 3.5% of women. This aligns with the well-documented pattern of men seeking preventive care less frequently than women, resulting in more missed diagnoses at earlier, more treatable stages. The prediabetes picture is equally skewed: roughly 41% of men compared to 32% of women have prediabetes in recent survey data — a gap that foreshadows continued higher diabetes incidence in men in the years ahead if not addressed.

The new GLP-1 treatment data from the CDC’s August 2025 Data Brief adds another dimension to the gender picture. In 2024, 27.2% of women and 25.9% of men with diagnosed diabetes were using injectable GLP-1 medications — meaning that despite men having both higher diabetes prevalence and higher undiagnosed rates, women are slightly more likely to be accessing the newest and most effective treatment class. This may partly reflect broader patterns of healthcare engagement, where women are more proactive in adopting new therapies. The takeaway for type 2 diabetes management in the US in 2026 is that the male diabetes burden is higher at every stage — prevalence, undiagnosed cases, prediabetes — yet men are systematically less connected to the healthcare system pathways that could intervene most effectively.

Type 2 Diabetes by Race and Ethnicity in the US 2026 — Racial Disparities Statistics

Racial and ethnic disparities in type 2 diabetes prevalence are among the most persistent and well-documented health inequities in the United States. The most current data from the CDC National Health Interview Survey (NHIS) and the CDC National Diabetes Statistics Report (January 2026) confirm that these disparities remain wide in 2026, with American Indian/Alaska Native, Black, and Hispanic Americans continuing to face substantially higher diabetes burdens than white Americans.

Source: CDC National Health Interview Survey 2019–2021, cited in CDC National Diabetes Statistics Report, January 2026; ADA About Diabetes Statistics, updated January 2026 (citing Jan 2026 CDC NDSR); ADA Economic Costs Report 2022; CDC NHIS Data Brief No. 537, August 2025

The racial disparities in type 2 diabetes prevalence captured in the most current US government data are stark and quantifiable. American Indian and Alaska Native adults bear the heaviest burden at 13.6% diagnosed diabetes prevalence — nearly double the rate seen in non-Hispanic white adults at 6.9%. Black Americans at 12.1% and Hispanic Americans at 11.7% are also dramatically more affected than white Americans, a pattern that research consistently links not to biological predisposition alone but to compounding structural risk factors: higher rates of obesity and food insecurity, residential environments with limited access to healthy foods and safe physical activity, reduced access to preventive and primary care, higher rates of poverty and socioeconomic stress, and a healthcare system that has historically delivered less proactive metabolic screening to minority communities.

The treatment picture in 2026 reveals a new and somewhat unexpected finding from the CDC’s August 2025 NHIS data brief: Hispanic adults with diabetes are actually the highest users of GLP-1 injectable medications at 31.3%, compared to the national average of 26.5% and Asian adults at only 12.1%. The very low GLP-1 uptake among Asian American diabetics is a significant access concern, given that Asian Americans develop type 2 diabetes at lower BMI thresholds than other groups — meaning traditional obesity-focused screening and treatment pathways may systematically miss them. Meanwhile, the finding that Black Americans with diabetes are the highest per capita spenders on direct healthcare costs — as documented in the ADA’s 2022 Economic Report — reflects the reality that Black patients are more likely to have more severe and complex diabetes presentations, more comorbidities, and less access to early-stage preventive care that reduces downstream costs.

Type 2 Diabetes by Age in the US 2026 — Age-Based Prevalence Statistics

Age is the single strongest demographic predictor of type 2 diabetes risk in the United States, and the federal surveillance data tells a clear story: prevalence rises sharply with each decade of life, becoming most concentrated among adults aged 60 and older. The data below comes from the CDC NHANES August 2021–August 2023 cycle — the most recently published laboratory-confirmed diabetes prevalence data available as of March 2026 — supplemented by the January 2026 CDC National Diabetes Statistics Report.

Source: CDC NCHS Data Brief No. 516, November 2024; CDC National Diabetes Statistics Report, January 21, 2026; ADA About Diabetes Statistics, January 2026; CDC NHIS Data Brief No. 537, August 2025

The age-based gradient in type 2 diabetes prevalence across the United States is dramatic by any standard. Among adults aged 20 to 39, total diabetes stands at just 3.6% — but that figure jumps almost five-fold to 17.7% among adults 40 to 59, and reaches 38.6% among those 60 and older. For seniors specifically, the CDC’s January 2026 report confirms that 28.8% of adults aged 65 and older have diagnosed diabetes — meaning that in a country where the senior population is growing rapidly due to aging baby boomers, the number of older Americans managing type 2 diabetes will increase substantially in the coming years regardless of prevention efforts among younger cohorts. The additional finding that 52.1% of all seniors have prediabetes — 31.3 million people over 65 — represents an extraordinary level of metabolic risk concentrated in precisely the age group that will place the highest demands on Medicare and the broader healthcare system.

The youth and young adult trends deserve particular attention in 2026. While type 2 diabetes in children under 18 remains relatively rare at approximately 14,490 new diagnoses per year, it is rising, and its consequences are far more severe than adult-onset type 2 because younger patients will live with the disease — and its progressive complications — for decades longer. Among young adults aged 20 to 39, the undiagnosed burden is proportionally high: of the 3.6% total diabetes prevalence in that group, more than a third is undiagnosed, reflecting lower healthcare engagement in younger adults. The GLP-1 treatment data from 2024 shows that adults aged 50 to 64 are the highest users of these medications at 33.3%, while seniors over 65 see uptake fall to just 20.8% — likely reflecting Medicare coverage restrictions, fixed income constraints, and provider hesitancy in the oldest patients.

Type 2 Diabetes Economic Burden in the US 2026 — Financial Cost Statistics

The economic cost of type 2 diabetes in the United States is measured in the hundreds of billions of dollars annually, consuming an almost incomprehensible share of the nation’s total healthcare resources. The most comprehensive federal analysis available — the American Diabetes Association’s Economic Costs of Diabetes in the U.S. in 2022, published in Diabetes Care in December 2023 — remains the authoritative benchmark, and its findings reflect a cost trajectory that is still climbing.

Source: ADA Economic Costs of Diabetes in the U.S. 2022, published Diabetes Care December 2023 (doi:10.2337/dci23-0085); NIDDK Diabetes Statistics, updated October 2025; AMA / JAMA Network Open, April 2025 (Tsipas et al., GLP-1 spending analysis)

The financial burden of type 2 diabetes in the United States is almost difficult to put into human terms. $412.9 billion per year — the total cost of diagnosed diabetes as of 2022 — means that every single day, the US spends more than $1.1 billion on a disease that is largely preventable. Of that, $306.6 billion is in direct medical costs: hospital inpatient care, physician visits, prescription medications, diabetes supplies, and treatment of the disease’s cascade of complications. The 1-in-4-healthcare-dollars figure — meaning one of every four dollars spent in the entire US healthcare system goes toward caring for people with diabetes — is a number that should anchor every policy conversation about health spending in America. And that figure is from 2022; with 40.1 million Americans now diagnosed versus the 25.5 million in the 2022 ADA economic analysis, the current-day total is almost certainly higher.

The pharmaceutical spending data is staggering in its own right. Spending on Ozempic (semaglutide) — originally a type 2 diabetes treatment — grew from $410 million in 2018 to $26.42 billion by 2023, according to research co-authored by the AMA and CDC published in JAMA Network Open in April 2025. Mounjaro (tirzepatide) went from $2.51 billion in its first year on market (2022) to $12.42 billion just one year later. These drugs deliver genuine clinical benefit — including 14.9% average body weight reduction for semaglutide and 20.9% for tirzepatide in clinical trials — but they come at extraordinary cost to payers, insurers, and uninsured patients. Without coverage, these medications carry monthly costs exceeding $1,000, creating a stark two-tiered access reality in which the Americans who would most benefit from GLP-1s — those with low incomes, inadequate insurance, and the highest diabetes and obesity burdens — are often the ones least able to afford them.

Type 2 Diabetes Complications in the US 2026 — Health Outcomes Statistics

Type 2 diabetes is not just a blood sugar disorder — it is a systemic disease that, when uncontrolled, damages the cardiovascular system, kidneys, eyes, nerves, and lower limbs simultaneously. The complications of poorly managed type 2 diabetes represent one of the largest drivers of healthcare utilization, disability, and premature death in the United States, and the data below reflects the most current available federal and peer-reviewed figures on diabetes complications as of March 2026.

Source: CDC National Diabetes Statistics Report, January 2026; SingleCare Diabetes Statistics, citing CDC and ADA (February 2025); Medical News Today / ADA Diabetes Care data; Type 2 DM Mortality Study, JACC: Advances, July 2025 (Ahmed et al., CDC WONDER database 1999–2023)

The complication data for type 2 diabetes makes clear that this is a disease whose true toll is measured in secondary conditions, disability, and premature death as much as in blood sugar readings. Cardiovascular disease kills more Americans with diabetes than anything else — accounting for 50 to 60% of all deaths in the diabetic population, with people who have type 2 diabetes facing a 1.5 to 2 times greater risk of developing heart disease. A July 2025 study published in JACC: Advances — analyzing CDC WONDER database death certificate data from 1999 to 2023 — documented that T2DM-related mortality is significantly higher in men than women and that Hispanic and non-Hispanic Black populations show disproportionately high mortality rates, with rural Americans also facing higher type 2 diabetes death rates than urban residents due to healthcare access gaps. These are not abstract statistics; they represent hundreds of thousands of preventable deaths and millions of preventable disability-years.

The kidney, eye, and limb complication data is equally sobering. An estimated 39.2% of all US adults with diagnosed diabetes — nearly 2 in 5 — also have chronic kidney disease, according to the CDC. Each year, approximately 50,000 Americans begin treatment for kidney failure caused by diabetes, and diabetes is responsible for 44% of all new kidney failure cases in the country. Diabetic retinopathy affects roughly 1 in 4 Americans aged 40 and older with diabetes, causing 12,000 to 24,000 new cases of blindness each year. And approximately 73,000 lower limb amputations per year are caused by diabetes — representing 60% of all non-traumatic lower limb amputations in the US. Many of these outcomes are preventable with timely diagnosis, consistent management, and access to the medications and monitoring tools that help maintain glycemic control — which is why the policy decisions being made about drug coverage, Medicaid funding, and preventive care access in 2026 have life-or-death consequences for millions of Americans.

Type 2 Diabetes and GLP-1 Medications in the US 2026 — Treatment Trend Statistics

Perhaps no development has reshaped the type 2 diabetes treatment landscape more dramatically in recent years than the rise of GLP-1 receptor agonist medications. Originally developed to manage blood sugar in type 2 diabetes, drugs like Ozempic (semaglutide), Mounjaro (tirzepatide), and Wegovy have become the most talked-about and prescribed pharmacological agents in America — and the most current federal data provides a detailed picture of exactly who is using them in 2026.

Source: CDC NCHS Data Brief No. 537, August 2025 (NHIS 2024 data); AMA / JAMA Network Open, April 2025 (Tsipas et al.); AJMC, August 2025 (GLP-1 prescribing patterns study); KFF Health Tracking Poll 2024; Gallup National Health and Well-Being Index (Patient Care Online, March 2026)

The GLP-1 revolution in type 2 diabetes treatment is the most significant pharmacological development in metabolic medicine in a generation — and the data confirms it is reshaping both clinical practice and national health metrics in real time. The CDC’s August 2025 Data Brief — based on the 2024 National Health Interview Survey, the most recent government data available — found that 26.5% of all adults with diagnosed diabetes (an estimated 6.9 million people) were using injectable GLP-1 medications. That is more than 1 in 4 Americans with diabetes already on this drug class, with uptake still rising. The Gallup 2025 National Health and Well-Being Index adds another critical data point: since early 2024, the share of US adults using GLP-1s specifically for weight loss more than doubled — from 5.8% to 12.4% — and US adult obesity rates fell from their 2022 peak of 39.9% to 37.0% in 2025, representing approximately 7.6 million fewer obese adults — the first statistically significant decline in US adult obesity in years.

However, the GLP-1 data comes with critical caveats that are central to the 2026 type 2 diabetes story. Despite obesity declining, the percentage of Americans with diagnosed diabetes has hit a record 13.8% in Gallup’s 2025 surveys — because GLP-1s do not reverse established diabetes diagnoses, and the disease pipeline of 115.2 million Americans with prediabetes continues to feed new cases. Access to these medications remains profoundly unequal: the $1,000+ per month cost without insurance makes them inaccessible to a large portion of the population with the highest metabolic risk. Asian Americans with diabetes — despite facing particular metabolic vulnerability — are accessing GLP-1s at only 12.1%, compared to 31.3% for Hispanic adults. And the August 2025 AJMC study found that semaglutide prescribing increased 10-fold between 2018 and 2022, with a significant share going to non-diabetic patients — raising questions about prioritization in a supply-constrained market. GLP-1 drugs are transforming the landscape of type 2 diabetes treatment in 2026, but their promise remains unevenly distributed.

Type 2 Diabetes by State in the US 2026 — Geographic Statistics

Type 2 diabetes prevalence varies significantly by state across the United States, reflecting deep regional differences in obesity rates, physical inactivity, food environments, poverty, access to healthcare, and racial/ethnic demographics. The most current state-level data comes from the CDC Behavioral Risk Factor Surveillance System (BRFSS) and the CDC PLACES project, with 2022 BRFSS data used in the 2025 County Health Rankings Annual Data Release.

Source: CDC BRFSS and PLACES Project, 2022 data (cited in County Health Rankings 2025 Annual Data Release); CDC National and State Diabetes Trends (archive); JACC: Advances, July 2025 (T2DM mortality study, CDC WONDER database)

The geographic distribution of type 2 diabetes across the United States is anything but random — it maps almost perfectly onto the country’s obesity belt, poverty belt, and healthcare access disparities. States like West Virginia, Mississippi, Alabama, and Louisiana consistently record diagnosed diabetes prevalence of 14 to 17% among adults — well above the national average of ~11.3% from NHANES — while states like Colorado, Utah, and Hawaii record rates as low as 7 to 8%. This near-doubling in prevalence between the lowest and highest states is not primarily explained by genetic differences. It reflects a geography of food insecurity, sedentary environments, limited access to primary care, higher uninsured rates, and concentrated poverty that creates far higher lifetime diabetes risk for residents of certain regions than others. The CDC’s own national and state diabetes trends page notes the direct correlation between county-level rates of diagnosed diabetes, obesity, and physical inactivity — three variables that move together across the American map with remarkable consistency.

The rural-urban divide in type 2 diabetes outcomes adds another urgent dimension to the geographic data. The July 2025 study in JACC: Advances — analyzing 24 years of death certificate data from the CDC WONDER database — found that T2DM-related mortality is significantly higher in rural areas than urban areas across the United States, driven by reduced access to endocrinologists and diabetes specialists, lower rates of preventive care visits, higher rates of poverty and unemployment, and limited availability of telemedicine infrastructure in remote communities. Rural Americans are more likely to be diagnosed late, less likely to receive specialist care, more likely to develop serious complications before receiving treatment, and less likely to have insurance coverage that makes medications like GLP-1 receptor agonists accessible. The geographic disparities in type 2 diabetes prevalence and mortality in 2026 are not acts of nature — they are the predictable outcomes of systematic underinvestment in health infrastructure across the communities that need it most.

Type 2 Diabetes Symptoms in the US 2026 — Warning Signs and Diagnosis Statistics

One of the most dangerous characteristics of type 2 diabetes is how quietly it develops. Unlike type 1, which typically presents with sudden and dramatic symptoms, type 2 diabetes can progress silently for years — and often does. The CDC estimates that 11 million Americans have undiagnosed type 2 diabetes, representing 27.6% of all adults with the condition. Understanding the recognized warning signs is critical to closing that diagnosis gap. The data below draws from the CDC, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the American Diabetes Association (ADA) — all updated through their most current 2025–2026 guidance pages.

Source: CDC Diabetes Symptoms and Testing Pages (updated 2025); NIDDK Diabetes Overview, updated October 2025; ADA Standards of Medical Care in Diabetes 2025; CDC National Diabetes Statistics Report, January 21, 2026

The symptom profile of type 2 diabetes is what makes it such a particularly dangerous public health problem — not its severity in acute episodes, but its invisibility in the years before diagnosis. The three classic warning signs — excessive thirst, frequent urination, and increased hunger — are textbook, but they are often mild in type 2 diabetes, developing so gradually that millions of people dismiss them as stress, aging, or normal variation. The CDC’s finding that 27.6% of adults with diabetes — 11 million people — are completely undiagnosed is a direct consequence of this slow, symptom-lite progression. Many people first learn they have type 2 diabetes during a routine blood draw for an entirely unrelated reason, or at the point where a complication like blurred vision, a non-healing wound, or a kidney function abnormality prompts a workup. At that point, the disease has often been silently damaging the cardiovascular system, kidneys, and nerves for years.

The diagnostic criteria most widely used in the US — an HbA1c of 6.5% or higher or a fasting blood glucose of 126 mg/dL or more, confirmed on two occasions — were established by the ADA and endorsed by the CDC and NIDDK. But the gateway to that test remains a problem: only about 1 in 3 adults at risk are screened regularly, and screening rates are lowest in the groups with the highest type 2 diabetes prevalence — including uninsured adults, racial and ethnic minorities, and men who avoid regular primary care visits. The prediabetes range of HbA1c 5.7% to 6.4% — which covers 115.2 million Americans per the January 2026 CDC report — is particularly critical because individuals in this range are largely asymptomatic and have an unambiguous opportunity to reverse course through lifestyle modification and the National Diabetes Prevention Program (DPP). The tragedy is that 8 in 10 people with prediabetes have no idea they have it.

Type 2 Diabetes Treatment in the US 2026 — Medication, Lifestyle, and Care Statistics

Treatment of type 2 diabetes in the United States has undergone a dramatic transformation over the past five years. Where the previous generation of management relied primarily on metformin, sulfonylureas, and insulin, the emergence of GLP-1 receptor agonists, SGLT2 inhibitors, and continuous glucose monitoring (CGM) technology has fundamentally expanded what is clinically achievable. The data below — drawn from the CDC, NIDDK, the ADA’s 2025 Standards of Care, and the most current surveillance research — reflects the full landscape of how type 2 diabetes is being treated in America in 2026.

Source: CDC NHIS Data Brief No. 537, August 2025 (GLP-1 use); NIDDK Diabetes Statistics, updated October 2025; CDC National Diabetes Prevention Program data, 2025; ADA Standards of Medical Care in Diabetes 2025 (published Diabetes Care January 2025); CDC Diabetes Treatment Pages, updated 2025; NIH NIDDK Bariatric Surgery and Diabetes page

The treatment landscape for type 2 diabetes in the United States in 2026 is more scientifically sophisticated than at any point in history — but the gap between what is clinically possible and what most patients are actually receiving remains wide. Metformin remains the most widely prescribed first-line medication for type 2 diabetes, used by roughly 1 in 3 adults with a diagnosis, and it remains the ADA’s recommended starting therapy for most patients due to its proven safety record, low cost, and cardiovascular neutrality. But the bigger story of 2026 is the explosion of GLP-1 and SGLT2 inhibitor prescribing: 26.5% of diabetic adults are now on injectable GLP-1s, and SGLT2 inhibitors — which offer simultaneous blood sugar reduction, heart failure protection, and kidney disease slowing — are gaining ground steadily. The ADA’s 2025 Standards of Medical Care now recommends GLP-1 receptor agonists and SGLT2 inhibitors as preferred agents not just for glucose control, but specifically for patients with established cardiovascular disease, heart failure, or chronic kidney disease — conditions that affect millions of Americans with type 2 diabetes simultaneously.

The prevention and self-management data, however, reveals the most consequential gap in the US type 2 diabetes response. The National Diabetes Prevention Program (DPP) — an evidence-based, CDC-recognized lifestyle intervention — reduces the risk of developing type 2 diabetes by 58% in high-risk adults and 71% in adults over 60. There are now more than 2,700 CDC-recognized DPP locations across the United States, and the program has been covered by Medicare since 2018 and by many private insurers. Yet only 3 to 4% of eligible adults with prediabetes are referred to the program by their physicians each year — an almost unfathomable gap between proven, affordable prevention and actual practice. Similarly, only 5 to 7% of adults with diagnosed diabetes ever complete a Diabetes Self-Management Education and Support (DSMES) program, despite overwhelming evidence that structured education improves glycemic control, reduces complications, and lowers long-term costs. The tools to prevent and manage type 2 diabetes in the US in 2026 are better than they have ever been. The challenge is not science — it is access, referral, coverage, and the structural barriers that keep the most effective interventions from reaching the people who need them most.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.